Nanotechnology-based delivery systems are also being explored to enhance the targeted delivery of uPAR inhibitors to tumor sites, thereby reducing systemic toxicity and improving therapeutic outcomes [2,10,176]. This evidence concerns the gene PLAUR and neoplasm.